SCHEMBL30129657

SCHEMBL30129657

c1ncc2c(n1)CCN2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1303005 1.00
SCHEMBL29388226 0.88 OR51E2 (0.33)
SCHEMBL2565061 0.88 OR51E2 (0.33)
SCHEMBL23070931 0.86 FKBP5 (0.35)
SCHEMBL31712935 0.79
SCHEMBL30978396 0.77
SCHEMBL31712928 0.76
SCHEMBL1448583 0.73 CHEK1 (0.37)
SCHEMBL30100337 0.73 CHEK1 (0.37)
SCHEMBL3046656 0.72 CDC7 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111655695-B Substituted furopyrimidine compounds as PDE1 inhibitors 达特神经科学有限公司 2025-05-27 CN claimed
CN-111655695-B Substituted furopyrimidine compounds as PDE1 inhibitors 达特神经科学有限公司 2025-05-27 CN disclosed
EP-4146190-A2 COMBINATION TREATMENT FOR FUMARATE-RELATED DISEASES Imcyse SA (BE) 2023-03-15 EP disclosed
CN-115531366-A Method of treating multiple sclerosis 渤健马萨诸塞州股份有限公司 2022-12-30 CN disclosed
CN-115501218-A Methods of treating multiple sclerosis 渤健马萨诸塞州股份有限公司 2022-12-23 CN disclosed